Form 4: Director Rachelle Jacques Reports uniQure Equity Activity

Director Rachelle Jacques acquired restricted share units and stock options while selling shares to cover tax obligations.

Summary

• Director Rachelle Jacques received a grant of 7,550 restricted share units (RSUs) on June 10, 2026.
• The director was granted 13,980 stock options with an exercise price of $26.82 on June 10, 2026.
• A total of 1,993 shares were sold on June 11, 2026, at a weighted average price of $27.06 to satisfy tax withholding requirements.
• Following these transactions, the director holds 33,903 ordinary shares directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting routine executive compensation and tax compliance rather than a strategic shift.

Positives

• Director maintains a significant equity stake of 33,903 shares.
• Equity-based compensation aligns director interests with long-term shareholder value.

Negatives

• The sale of 1,993 shares, while non-discretionary, reduces the total direct share count.

Risks

• Vesting of RSUs and options is contingent upon the director's continued relationship with the issuer.
• Market price volatility could impact the value of the granted options and future RSU settlements.

Future Outlook

The director's equity grants vest 100% on the first anniversary of the grant date, June 10, 2027, contingent on continued service.

Industry Context

StockSavvy.ai notes that this filing represents standard executive compensation activity within the biotechnology sector, where equity-based incentives are common to retain board members and align them with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The use of automatic sell-to-cover transactions for tax obligations is a standard practice for corporate insiders in the pharmaceutical and biotech industries.
• The one-year cliff vesting schedule for director equity is consistent with typical corporate governance practices for mid-cap biotech firms.

Stakeholder Impact

• Shareholders should view this as standard compensation activity with no immediate impact on company operations or strategy.

Next Steps

• Vesting of restricted share units on June 10, 2027.
• Vesting of stock options on June 10, 2027.

Key Dates

Keywords

uniQure, QURE, insider trading, Form 4, equity compensation, biotech